Acne Treatment Manufacturing OTC in the US - Industry Market Research Report

Come to a head: Manufacturers will face greater competition from prescription acne products and laser treatments

The Acne Treatment Manufacturing OTC industry benefits from fairly stable demand because acne-prone individuals consider them a necessary expense. However, adolescents comprise the industry's largest market. High unemployment levels and low disposable incomes within this shrinking age bracket have caused sales of over-the-counter (OTC) acne treatments to drop. Moreover, the industry has been undercut by less expensive goods produced abroad. Increasingly, manufacturers have sought to locate internationally to take advantage of lower labor costs, causing imports to expand as a share of domestic demand. So, industry-wide revenue has been decreasing at a CAGR of 1.2% over the past five years, including an estimated 1.1% increase in 2023, and is expected to total $413.6 million in 2023. Further, profit is projected to decrease to 19.9% in 2023.

This industry manufactures over-the-counter (i.e., nonprescription) acne treatment and medication. Manufacturers include active ingredients like benzoyl peroxide, salicylic acid, sulfur, resorcinol or a combination of such ingredients and a range of inactive ingredients like emollients and surfactants. OTC acne treatments are mostly topical and are manufactured as gels, moisturizers, lotions, creams, soaps and pads.

This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.